ALK B ALK-abello A/S Class B

Decision to complete share split at a ratio of 1:20

Decision to complete share split at a ratio of 1:20



At the annual general meeting of ALK-Abelló (ALKB:DC / OMX: ALK B / AKABY / AKBLF) on 16 March 2022, the general meeting adopted to amend the denomination of each share’s nominal value from DKK 10 to DKK 0.50 or multiples thereof. The amendment of the shares’ nominal value enables the Board of Directors of ALK-Abelló A/S to carry out a share split.

On that basis, the Board of Directors has decided to complete a share split at a ratio of 1:20 entailing that each existing share of a nominal value of DKK 10 will be split into 20 new shares of a nominal value of DKK 0.50 each. Following the share split, the company’s share capital of DKK 111,411,960 will be divided into 18,415,200 A shares, 1,841,520 AA shares and 202,567,200 B shares, each having a nominal value of DKK 0.50. Upon completion of the share split, each A share and AA share of a nominal value of DKK 0.50 shall have 10 votes and each B share of a nominal value of DKK 0.50 shall have one vote.

The planned schedule for completion of the share split of the company’s B shares listed at Nasdaq Copenhagen will be as follows:

  • 25 March 2022: Last day of trading at Nasdaq Copenhagen via the existing ISIN code DK0060027142
  • 28 March 2022: First day of trading at Nasdaq Copenhagen via the new ISIN code DK0061802139
  • 29 March 2022: The new ISIN code and face value (nominal denomination) of the B shares are registered with VP Securities A/S (Euronext)



Following the share split, the ticker symbol for ALK-Abelló’s B shares will continue to be “ALK B”. The company’s A and AA shares are not listed and, consequently, new ISIN codes etc. are not created for these shares.

ALK-Abelló A/S

For further information, please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Jeppe Ilkjær, mobile

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,600 people worldwide and is listed on Nasdaq Copenhagen. Find more information at

Attachment



EN
16/03/2022

Underlying

ALK BALK-abello A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-abello A/S Class B

Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting solid start to the year

We expect a solid Q1 report, with likely c11% organic growth as well as good margin progress supporting the 2025 guidance. Based on its footprint, we see minimal effect in case of tariffs on pharmaceuticals, with the biggest risk coming from potential reciprocal ones from Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
04/25/25 April 25, 2025 1 EN
Free Trial
ALK B ALK-abello A/S ...

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,606 shares at 155.680DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

ALK B ALK-ABELLO A/S CLASS B
02/24/25 February 24, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Sales trump one-offs in Q4

While one-off costs took the initial focus (albeit broadly pre-warned), a solid underlying performance in Q4 was anchored in the important European tablet sales, which exceeded expectations. We find the 2025 guidance in line with expectations, but see upside risk to consensus on the top line given strong momentum in tablet sales in Europe. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/19/25 February 19, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Expecting strong year end

We expect a strong Q4, with c12% organic revenue growth YOY, but the EBIT margin to be under pressure from well flagged one-offs related to optimisation initiatives and revision of its Chinese plans. We expect the 2025 guidance to be in line with expectations and its long-term strategy announced last year for >10% organic revenue growth and a c25% EBIT margin. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
02/13/25 February 13, 2025 1 EN
Jesper Ingildsen
  • Jesper Ingildsen
Free Trial
ALK B ALK-abello A/S ...

ALK-Abello (Buy, TP: DKK190.00) - Solid momentum reaffirmed

We find ALK’s solid momentum reaffirmed with the strong Q3 results, where higher European tablet sales more than offset the softness in SCIT/SLIT-drops. We believe the results also confirmed continued profitability improvement, leaving ALK on track to meet its 2025 EBIT margin target of c25% and in a position of strength to invest in growth opportunities, with the Neffy deal as a good example. We reiterate our BUY and DKK190 target price.

ALK B ALK-ABELLO A/S CLASS B
11/14/24 November 14, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch